CD38 and Miyoshi myopathy: This shift will be crucial not only for relapsed/refractory MM but also for newly diagnosed disease, as our data show that plasma cell identity escape can already be detected in some NDMM cases and is associated with early resistance to IMiDs and anti-CD38 therapies.